Loading…
Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective
Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) an...
Saved in:
| Published in: | Cancers 2022-10, Vol.14 (19), p.4828 |
|---|---|
| Main Authors: | , , |
| Format: | Article |
| Language: | English |
| Subjects: | |
| Citations: | Items that this one cites Items that cite this one |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| cited_by | cdi_FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13 |
|---|---|
| cites | cdi_FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13 |
| container_end_page | |
| container_issue | 19 |
| container_start_page | 4828 |
| container_title | Cancers |
| container_volume | 14 |
| creator | Puccini, Alberto Seeber, Andreas Berger, Martin D |
| description | Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) and biomarker-driven patient selection. Moreover, progress in molecular diagnostics but also improvement in surgical techniques and local ablative treatments significantly contributed to this success. However, novel therapeutic approaches are needed to further improve outcome in patients diagnosed with metastatic CRC. Besides the established biomarkers for mCRC, such as microsatellite instability (MSI) or mismatch repair deficiency (dMMR),
, sidedness and
amplification, new biomarkers have to be identified to better select patients who derive the most benefit from a specific treatment. In this review, we provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual mCRC patient in the near future. |
| doi_str_mv | 10.3390/cancers14194828 |
| format | article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9564318</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A745272084</galeid><sourcerecordid>A745272084</sourcerecordid><originalsourceid>FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13</originalsourceid><addsrcrecordid>eNptks9PHCEUx4lpU83Wc2-GpJdeVmFgBuihiW5qNdFUU--EZR6KzsIWZkz63_dttVZN4cCvz_f78h6PkA-c7Qth2IF3yUOpXHIjdaO3yE7DVDPvOiPfPNtvk91abxkOIbjq1DuyLbpGMNXyHXJ-FPPKlTv0oTHRcxhdHd0YPV3kIRfwoxvo4k-gz_QHvkyVXk6ZutTT42mcCtAL1K4RjPfwnrwNbqiw-7jOyNXx16vFyfzs-7fTxeHZ3Eutx7lveg0Qljw0EJiHpZZGi7aTPRgDjONRSdm6oLn2oZeulTJw0fZcObPkYka-PNiup-UKeg9pLG6w6xIxlV82u2hfvqR4Y6_zvTUYQ3CNBp8eDUr-OUEd7SpWD8PgEuSp2kY1LTedES2iH1-ht3kqCbPbUBLryJn6R127AWxMIWNcvzG1h0q2SDItkdr_D4Wzh1X0OUGIeP9CcPAg8CXXWiA85ciZ3fSAfdUDqNh7Xpon_u-Pi9-0-q0D</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2724230107</pqid></control><display><type>article</type><title>Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective</title><source>Publicly Available Content Database</source><source>PubMed Central</source><creator>Puccini, Alberto ; Seeber, Andreas ; Berger, Martin D</creator><creatorcontrib>Puccini, Alberto ; Seeber, Andreas ; Berger, Martin D</creatorcontrib><description>Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) and biomarker-driven patient selection. Moreover, progress in molecular diagnostics but also improvement in surgical techniques and local ablative treatments significantly contributed to this success. However, novel therapeutic approaches are needed to further improve outcome in patients diagnosed with metastatic CRC. Besides the established biomarkers for mCRC, such as microsatellite instability (MSI) or mismatch repair deficiency (dMMR),
, sidedness and
amplification, new biomarkers have to be identified to better select patients who derive the most benefit from a specific treatment. In this review, we provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual mCRC patient in the near future.</description><identifier>ISSN: 2072-6694</identifier><identifier>EISSN: 2072-6694</identifier><identifier>DOI: 10.3390/cancers14194828</identifier><identifier>PMID: 36230751</identifier><language>eng</language><publisher>Switzerland: MDPI AG</publisher><subject>Biomarkers ; Cancer ; Cancer therapies ; Care and treatment ; Chemotherapy ; Colorectal cancer ; Colorectal carcinoma ; DNA methylation ; ErbB-2 protein ; Immune checkpoint inhibitors ; Immunosuppressive agents ; Medical prognosis ; Metastases ; Metastasis ; Microsatellite instability ; Mismatch repair ; Mutation ; Patient outcomes ; Patients ; Precision medicine ; Review ; Tumors</subject><ispartof>Cancers, 2022-10, Vol.14 (19), p.4828</ispartof><rights>COPYRIGHT 2022 MDPI AG</rights><rights>2022 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>2022 by the authors. 2022</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13</citedby><cites>FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13</cites><orcidid>0000-0002-2492-4043 ; 0000-0001-8529-7824</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.proquest.com/docview/2724230107/fulltextPDF?pq-origsite=primo$$EPDF$$P50$$Gproquest$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.proquest.com/docview/2724230107?pq-origsite=primo$$EHTML$$P50$$Gproquest$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,25753,27924,27925,37012,37013,44590,53791,53793,74998</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36230751$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Puccini, Alberto</creatorcontrib><creatorcontrib>Seeber, Andreas</creatorcontrib><creatorcontrib>Berger, Martin D</creatorcontrib><title>Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective</title><title>Cancers</title><addtitle>Cancers (Basel)</addtitle><description>Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) and biomarker-driven patient selection. Moreover, progress in molecular diagnostics but also improvement in surgical techniques and local ablative treatments significantly contributed to this success. However, novel therapeutic approaches are needed to further improve outcome in patients diagnosed with metastatic CRC. Besides the established biomarkers for mCRC, such as microsatellite instability (MSI) or mismatch repair deficiency (dMMR),
, sidedness and
amplification, new biomarkers have to be identified to better select patients who derive the most benefit from a specific treatment. In this review, we provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual mCRC patient in the near future.</description><subject>Biomarkers</subject><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Chemotherapy</subject><subject>Colorectal cancer</subject><subject>Colorectal carcinoma</subject><subject>DNA methylation</subject><subject>ErbB-2 protein</subject><subject>Immune checkpoint inhibitors</subject><subject>Immunosuppressive agents</subject><subject>Medical prognosis</subject><subject>Metastases</subject><subject>Metastasis</subject><subject>Microsatellite instability</subject><subject>Mismatch repair</subject><subject>Mutation</subject><subject>Patient outcomes</subject><subject>Patients</subject><subject>Precision medicine</subject><subject>Review</subject><subject>Tumors</subject><issn>2072-6694</issn><issn>2072-6694</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2022</creationdate><recordtype>article</recordtype><sourceid>PIMPY</sourceid><recordid>eNptks9PHCEUx4lpU83Wc2-GpJdeVmFgBuihiW5qNdFUU--EZR6KzsIWZkz63_dttVZN4cCvz_f78h6PkA-c7Qth2IF3yUOpXHIjdaO3yE7DVDPvOiPfPNtvk91abxkOIbjq1DuyLbpGMNXyHXJ-FPPKlTv0oTHRcxhdHd0YPV3kIRfwoxvo4k-gz_QHvkyVXk6ZutTT42mcCtAL1K4RjPfwnrwNbqiw-7jOyNXx16vFyfzs-7fTxeHZ3Eutx7lveg0Qljw0EJiHpZZGi7aTPRgDjONRSdm6oLn2oZeulTJw0fZcObPkYka-PNiup-UKeg9pLG6w6xIxlV82u2hfvqR4Y6_zvTUYQ3CNBp8eDUr-OUEd7SpWD8PgEuSp2kY1LTedES2iH1-ht3kqCbPbUBLryJn6R127AWxMIWNcvzG1h0q2SDItkdr_D4Wzh1X0OUGIeP9CcPAg8CXXWiA85ciZ3fSAfdUDqNh7Xpon_u-Pi9-0-q0D</recordid><startdate>20221003</startdate><enddate>20221003</enddate><creator>Puccini, Alberto</creator><creator>Seeber, Andreas</creator><creator>Berger, Martin D</creator><general>MDPI AG</general><general>MDPI</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7T5</scope><scope>7TO</scope><scope>7XB</scope><scope>8FE</scope><scope>8FH</scope><scope>8FK</scope><scope>8G5</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BBNVY</scope><scope>BENPR</scope><scope>BHPHI</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>GNUQQ</scope><scope>GUQSH</scope><scope>H94</scope><scope>HCIFZ</scope><scope>LK8</scope><scope>M2O</scope><scope>M7P</scope><scope>MBDVC</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>Q9U</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-2492-4043</orcidid><orcidid>https://orcid.org/0000-0001-8529-7824</orcidid></search><sort><creationdate>20221003</creationdate><title>Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective</title><author>Puccini, Alberto ; Seeber, Andreas ; Berger, Martin D</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2022</creationdate><topic>Biomarkers</topic><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Chemotherapy</topic><topic>Colorectal cancer</topic><topic>Colorectal carcinoma</topic><topic>DNA methylation</topic><topic>ErbB-2 protein</topic><topic>Immune checkpoint inhibitors</topic><topic>Immunosuppressive agents</topic><topic>Medical prognosis</topic><topic>Metastases</topic><topic>Metastasis</topic><topic>Microsatellite instability</topic><topic>Mismatch repair</topic><topic>Mutation</topic><topic>Patient outcomes</topic><topic>Patients</topic><topic>Precision medicine</topic><topic>Review</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Puccini, Alberto</creatorcontrib><creatorcontrib>Seeber, Andreas</creatorcontrib><creatorcontrib>Berger, Martin D</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Immunology Abstracts</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>ProQuest SciTech Collection</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>Research Library (Alumni Edition)</collection><collection>ProQuest Central (Alumni)</collection><collection>ProQuest Central</collection><collection>ProQuest Central Essentials</collection><collection>Biological Science Collection</collection><collection>AUTh Library subscriptions: ProQuest Central</collection><collection>ProQuest Natural Science Collection</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central</collection><collection>ProQuest Central Student</collection><collection>Research Library Prep</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>SciTech Premium Collection (Proquest) (PQ_SDU_P3)</collection><collection>ProQuest Biological Science Collection</collection><collection>ProQuest Research Library</collection><collection>Biological Science Database</collection><collection>Research Library (Corporate)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>ProQuest Central Basic</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancers</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Puccini, Alberto</au><au>Seeber, Andreas</au><au>Berger, Martin D</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective</atitle><jtitle>Cancers</jtitle><addtitle>Cancers (Basel)</addtitle><date>2022-10-03</date><risdate>2022</risdate><volume>14</volume><issue>19</issue><spage>4828</spage><pages>4828-</pages><issn>2072-6694</issn><eissn>2072-6694</eissn><abstract>Colorectal cancer (CRC) is the third most frequent cancer worldwide, and its incidence is steadily increasing. During the last two decades, a tremendous improvement in outcome has been achieved, mainly due to the introduction of novel drugs, targeted treatment, immune checkpoint inhibitors (CPIs) and biomarker-driven patient selection. Moreover, progress in molecular diagnostics but also improvement in surgical techniques and local ablative treatments significantly contributed to this success. However, novel therapeutic approaches are needed to further improve outcome in patients diagnosed with metastatic CRC. Besides the established biomarkers for mCRC, such as microsatellite instability (MSI) or mismatch repair deficiency (dMMR),
, sidedness and
amplification, new biomarkers have to be identified to better select patients who derive the most benefit from a specific treatment. In this review, we provide an overview about therapeutic relevant and established biomarkers but also shed light on potential promising markers that may help us to better tailor therapy to the individual mCRC patient in the near future.</abstract><cop>Switzerland</cop><pub>MDPI AG</pub><pmid>36230751</pmid><doi>10.3390/cancers14194828</doi><orcidid>https://orcid.org/0000-0002-2492-4043</orcidid><orcidid>https://orcid.org/0000-0001-8529-7824</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2072-6694 |
| ispartof | Cancers, 2022-10, Vol.14 (19), p.4828 |
| issn | 2072-6694 2072-6694 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_9564318 |
| source | Publicly Available Content Database; PubMed Central |
| subjects | Biomarkers Cancer Cancer therapies Care and treatment Chemotherapy Colorectal cancer Colorectal carcinoma DNA methylation ErbB-2 protein Immune checkpoint inhibitors Immunosuppressive agents Medical prognosis Metastases Metastasis Microsatellite instability Mismatch repair Mutation Patient outcomes Patients Precision medicine Review Tumors |
| title | Biomarkers in Metastatic Colorectal Cancer: Status Quo and Future Perspective |
| url | http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-07T17%3A52%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Biomarkers%20in%20Metastatic%20Colorectal%20Cancer:%20Status%20Quo%20and%20Future%20Perspective&rft.jtitle=Cancers&rft.au=Puccini,%20Alberto&rft.date=2022-10-03&rft.volume=14&rft.issue=19&rft.spage=4828&rft.pages=4828-&rft.issn=2072-6694&rft.eissn=2072-6694&rft_id=info:doi/10.3390/cancers14194828&rft_dat=%3Cgale_pubme%3EA745272084%3C/gale_pubme%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c488t-c2d8eefb1f2ef0ceb84983564de99e018497445af818cfd4a544f135d17a9b13%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=2724230107&rft_id=info:pmid/36230751&rft_galeid=A745272084&rfr_iscdi=true |